Infectious disease
The U.S. FDA reversed itself Sunday following pressure from the White House and announced an Emergency Use Authorization for convalescent plasma as a treatment for patients who have contracted COVID-19.
It was a relatively quiet week for clinical trial news. Here’s a look.
Following approval of its coronavirus vaccine, the first in the world, Russia plans to initiate a new study involving 40,000 people as the country looks to boost production and distribute the drug to patients in that country, as well as to patients in countries it has struck deals with.
Today’s data describes key safety and immunogenicity data from the U.S. Phase I study for BNT162b.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 21, 2020.
Pharmaceutical industry investors are betting on contract development and manufacturing organizations (CDMOs) this year, as they shift their focus from contract research organizations (CRO).
The study concludes that they can detect almost 50% of COVID-19 cases a day before enrollees in the study reported the onset of symptoms, and they do so with 70% specificity.
Two generic anti-inflammatory drugs typically used in asthma treatments are being proposed for use with COVID-19 because of their potential to dampen disease progression and severity.
Point-of-care testing is a critical tool in the battle against COVID-19, and researchers in Indiana are working around the clock to deliver rapid tests with high specificity.
Regeneron will distribute REGN-COV-2 in the U.S. and Roche will handle distribution outside the U.S.
PRESS RELEASES